Market-Moving News for June 14th
$ADBE
$BPTH
$MOLN
Computer Software: Prepackaged Software
Technology
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ADBE alert in real time by email
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/3/2026 | $330.00 | Overweight → Neutral | Piper Sandler | |
| 1/27/2026 | $13.00 | Buy | H.C. Wainwright | |
| 1/13/2026 | Outperform → Perform | Oppenheimer | ||
| 1/12/2026 | $290.00 | Sell | Goldman | |
| 1/9/2026 | $375.00 | Outperform → Market Perform | BMO Capital Markets | |
| 1/5/2026 | $400.00 | Buy → Hold | Jefferies | |
| 12/15/2025 | $310.00 | Sector Weight → Underweight | KeyBanc Capital Markets | |
| 12/15/2025 | $405.00 → $400.00 | Outperform | BMO Capital Markets |
Piper Sandler downgraded Adobe from Overweight to Neutral and set a new price target of $330.00
H.C. Wainwright initiated coverage of Molecular Partners AG with a rating of Buy and set a new price target of $13.00
Oppenheimer downgraded Adobe from Outperform to Perform
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumorsMP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine expert Prof. Ken Herrmann, M.D. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company deve
Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program to be presented at TWC 2026Phase 2 investigator-initiated trial of MP0317 now open with patient dosing ongoing, exploring MP0317 in combination with standard-of-care for patients with cholangiocarcinomaPhase 1/2a trial of multi-specific T cell engager MP0533 ongoing, update on clinical development path planned for H1 2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN
Multi-year strategic partnership brings together Runway's innovative video models with Adobe's industry-leading creative tools to power the next generation of AI-driven video workflows for creators, Hollywood studios, streamers, media companies, brands and enterprises Adobe will be Runway's preferred API creativity partner, offering creators exclusive early access to Runway's new models – starting with Runway's Gen-4.5 which is now available in the Adobe Firefly app Adobe and Runway will collaborate to develop specialized AI capabilities for professional video workflows that will be exclusively available in Adobe applications starting with Adobe Firefly Adobe (NASDAQ:ADBE), the gl
4 - ADOBE INC. (0000796343) (Issuer)
4 - ADOBE INC. (0000796343) (Issuer)
4 - ADOBE INC. (0000796343) (Issuer)
4 - ADOBE INC. (0000796343) (Issuer)
4 - ADOBE INC. (0000796343) (Issuer)
4 - ADOBE INC. (0000796343) (Issuer)
SCHEDULE 13G/A - ADOBE INC. (0000796343) (Subject)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
8-K - ADOBE INC. (0000796343) (Filer)
Adobe delivers new AI innovations and industry's top AI models across Creative Cloud apps – including Photoshop, Lightroom, Premiere and Illustrator – empowering creative professionals to save time, meet the rising demand for creative content and work with greater power, precision and control. New AI Assistant in Photoshop, powered by agentic AI, enables creative professionals to scale their work and free up time by instructing the assistant to help on a series of repetitive tasks and surface personalized recommendations, all while maintaining creative control. New AI-powered capabilities in Firefly Boards, including image upscaling and prompt generation, empower creative teams to mo
Adobe Firefly, the all-in-one AI creative studio for multimedia, now brings creators fully licensed audio track creation, crystal clear voiceover generation and an end-to-end timeline-based video editor Adobe Firefly brings creators the top AI models in one place, at one price – including the new Firefly Image Model 5 for photorealism and prompt-based editing; new partner models from ElevenLabs, Google and Topaz Labs; and new Firefly Custom Models that generate in creators' own personal style Adobe previews Project Moonlight in Firefly, a conversational AI assistant that works across Adobe's creative apps and creators' social channels to deliver content insights and personalized reco
Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced the appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the company's Executive Committee, effective October 1, 2025. Martin brings a wealth of experience in oncology drug dev
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumorsMP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine expert Prof. Ken Herrmann, M.D. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company deve
Exceeds target for FY2025 Digital Media ending ARR and targets FY2026 Total Adobe ending ARR to grow over 10% Delivers record operating cash flows of over $10 billion in FY2025 Adobe (NASDAQ:ADBE), the global technology leader that unleashes creativity and productivity for individuals and businesses through innovative platforms and tools, today reported financial results for its fourth quarter and FY2025 ended Nov. 28, 2025. "Adobe's record FY2025 results reflect our growing importance in the global AI ecosystem and the rapid adoption of our AI-driven tools," said Shantanu Narayen, chair and CEO, Adobe. "By advancing our innovative generative and agentic platforms and expanding our cu
Today, Adobe (NASDAQ:ADBE) announced it will release its fourth quarter and fiscal year 2025 results after the market closes on Wednesday, Dec. 10, 2025, followed by a conference call with investors from 2-3 p.m. Pacific Time. The conference call will be streamed live on the Adobe Investor Relations Site. Following the call, a recording and related materials will be available on the site. Adobe uses its website as a channel of distribution of material company information. Financial, product and other material information regarding the company is routinely posted on and accessible at www.adobe.com/ADBE. About Adobe Adobe is changing the world through digital experiences. For more informat
SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)
SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)
SC 13D/A - MOLECULAR PARTNERS AG (0001745114) (Subject)